Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Axial Spondyloarthritis (axSpA) Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?
The axial spondyloarthritis (axspa) market size has experienced robust growth in recent years. This market is anticipated to expand from $6.56 billion in 2025 to $7.09 billion in 2026, at a compound annual growth rate (CAGR) of 8.1%. The historical expansion of the market can be ascribed to several factors, including heightened awareness of inflammatory spinal disorders, increased utilization of TNF inhibitors, better access to diagnostic imaging, advancements in rheumatology specialty care, and initiatives promoting greater treatment adherence.
The axial spondyloarthritis (axspa) market size is anticipated to experience robust growth over the next few years. It is projected to expand to $9.83 billion by 2030, achieving a compound annual growth rate (CAGR) of 8.5%. This expansion during the forecast period is driven by the increasing integration of JAK inhibitors and IL therapies, greater investments in personalized medicine, the broadening of early screening initiatives, the rising application of digital disease monitoring platforms, and continuous breakthroughs in biologic drug development. Significant trends expected in the forecast period encompass a wider embrace of biologic treatments, a growing reliance on targeted anti-inflammatory medications, an amplified emphasis on timely diagnosis and disease surveillance, the expansion of individualized treatment methodologies, and better incorporation of digital health tools.
Get A Free Sample Report With In-Depth Market Insights:
Axial Spondyloarthritis (axSpA) Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The expanding aging population is anticipated to boost the axial spondyloarthritis (axSpa) market in the future. An aging population signifies a demographic shift where older individuals constitute a larger segment or a greater percentage of the total population. Managing axSpA effectively in this demographic offers advantages such as enhanced joint function and mobility, better quality of life, prevention of spinal structural damage, lower healthcare expenditures, avoidance of disability, and refined treatment approaches. For example, Age UK, a UK-registered charity, reported 11 million people aged over 65 in England in 2023. This figure is forecast to grow by 10% over the next five years and by 32% by 2043, translating to 1.1 and 3.5 million additional people, respectively. Furthermore, the 85+ age group, which typically requires more health and care services, is also expected to experience significant growth, rising by 8.2% within the next five years and by 62.7% by 2043, representing 126,000 and 956,000 more individuals, respectively. Consequently, the rising number of elderly people is fueling the expansion of the axial spondyloarthritis (axSpa) market.
Axial Spondyloarthritis (axSpA) Market Segments: Where Is Growth Concentrated?
The axial spondyloarthritis (axspa) market covered in this report is segmented –
1) By Type: Ankylosing Spondylitis (AS), Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
2) By Commercialized Therapies: Anti-Tumor Necrosis Factor Therapy (TNF), Anti-Interleukin Therapy (IL), Anti-Janus Kinase Therapy (JAK)
3) By Dosage Form: Tablets, Injections
4) By Treatment: Tumor Necrosis Factor (TNF) Alpha Inhibitors, Non-Steroidal Anti-Inflammatory Drugs (NSAID), Interleukin Blockers
5) By End-Use: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacy Stores
Subsegments:
1) By Ankylosing Spondylitis (AS): Early-stage AS, Advanced-stage AS
2) By Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Active nr-axSpA, Low-Disease-Activity nr-axSpA
Axial Spondyloarthritis (axSpA) Market Innovation Trends Shaping Future Development
Leading companies in the axial spondyloarthritis (axSpA) market are concentrating on creating innovative solutions, including advanced biologic drug therapies. This focus aims to address the growing need for potent treatments that specifically target inflammation and enhance long-term disease management. Unlike conventional anti-inflammatory drugs, which primarily alleviate symptoms without directly impacting the underlying immune causes, these biologic therapies work by modulating particular immune pathways, providing a more precise treatment method. An example of this progress occurred in June 2023 when UCB SA, a pharmaceutical company based in Belgium, obtained marketing authorization from the New European Commission for BIMZELX (bimekizumab). This drug is indicated for adults suffering from active axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS), particularly those showing objective signs of inflammation, such as elevated C-reactive protein. These approvals by the European Union (EU) mark the initial global marketing licenses for this drug in the context of axial spondyloarthritis.
Axial Spondyloarthritis (axSpA) Market Key Participants And Competitive Landscape
Major companies operating in the axial spondyloarthritis (axspa) market are AbbVie Inc., Pfizer Inc., Novartis AG, Eli Lilly and Company, Johnson & Johnson, UCB S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Sanofi S.A., Regeneron Pharmaceuticals Inc., Merck & Co. Inc., GSK plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Biogen Inc., Amgen Inc., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Kyowa Kirin Co. Ltd., Janssen Pharmaceuticals, Acelyrin Inc.
View The Full Axial Spondyloarthritis (axSpA) Market Report:
Axial Spondyloarthritis (axSpA) Market Largest Region: Which Geography Holds The Biggest Share?
North America was the largest region in the axial spondyloarthritis(axSpA) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the axial spondyloarthritis (axspa) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model







